靶向治疗时代的减瘤性肾切除术:综述
本综述回顾了减瘤性肾切除术在转移性肾细胞癌治疗中的角色演变。靶向治疗较细胞因子免疫治疗提高了缓解率、中位生存期和总体预后,但减瘤性肾切除术联合靶向治疗的持续价值仍存争议。
要点
- 靶向治疗较免疫治疗改善了缓解率、中位生存期和总体预后。
- 两项随机对照试验证明减瘤性肾切除术联合免疫治疗可提供独立生存获益。
- 靶向治疗时代减瘤性肾切除术作为可行手术治疗方法的持续作用仍有争议。
核心结论
- 靶向治疗改善了转移性肾细胞癌的缓解率、中位生存期和总体预后,但减瘤性肾切除术在靶向治疗时代的持续作用仍存在争议。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 靶向治疗较细胞因子免疫治疗提高了缓解率、中位生存期和总体预后。
- 两项随机对照试验证明减瘤性肾切除术联合免疫治疗可提供独立生存获益。
- 从细胞因子免疫治疗转向靶向治疗后,减瘤性肾切除术作为可行手术治疗方法的持续作用仍有争议。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the pre-targeted therapy era, palliative cytoreductive nephrectomy combined with cytokine immunotherapy was the standard treatment protocol for the management of metastatic renal cell carcinoma. The introduction of targeted therapies has improved response rates, median survival and overall prognosis when compared to immunotherapy. The role of cytoreductive nephrectomy in providing an independent survival advantage when used alongside immunotherapy has been demonstrated by two randomised controlled trials. However, with the new shift in improved treatment outcomes from cytokine immunotherapy to targeted therapies, the continuing role of cytoreductive nephrectomy as a viable surgical treatment method remains controversial.
引用
- Pindoria N, Raison N, Blecher G, et al. Cytoreductive nephrectomy in the era of targeted therapies: a review. BJU Int. 2017. PMID: 28371084. doi:10.1111/bju.13860
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。